


Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

CLAIM LISTING

1. (Currently amended) A compound of formula I




formula I

wherein

R¹ is hydrogen or C₁₋₆-alkyl;

R² is hydrogen or C₁₋₆-alkyl;

L is



wherein R⁴ is hydrogen or C₁₋₆ alkyl;

p is 0 or 1;

q, s, t, u are independently from each other 0, 1, 2, 3 or 4;


r is 1;

the sum q + r + s + t + u is 0, 1, 2, 3, or 4;

Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

R^9 , R^{10} , R^{11} , and R^{12} are independently from each other hydrogen or C_{1-6} alkyl;

Q is $>N-R^{13}$ or




wherein o is 0, 1 or 2;

T is $-N(R^{15})(R^{16})$ or hydroxyl;

R^{13} , R^{14} , and R^{16} are independently from each other hydrogen or C_{1-6} alkyl;

R^{14} is hydrogen, aryl or hetaryl;

or L is



p is 0 or 1;

q, s, t, u are independently from each other 0, 1, 2, 3 or 4;


r is 0 or 1;

the sum $q + r + s + t + u$ is 0, 1, 2, 3, or 4;

R^9 , R^{10} , R^{11} , and R^{12} are independently from each other hydrogen or C_{1-6} alkyl;

Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

Q is $>\text{N-R}^{13}$ or




wherein o is 0, 1 or 2;

T is $-\text{N}(\text{R}^{15})(\text{R}^{16})$ or hydroxyl;

R^{13} , R^{15} , and R^{16} are independently from each other hydrogen or C_{1-6} alkyl;

R^{14} is hydrogen, aryl or hetaryl;

G is $-\text{O}-(\text{CH}_2)_k-\text{R}^{17}$,




wherein R^{17} , R^{18} , R^{19} , R^{20} and R^{21} independently from each other are hydrogen, halogen, aryl, hetaryl, C_{1-6} -alkyl or C_{1-6} -alkoxy;

k is 0, 1 or 2;

J is $-\text{O}-(\text{CH}_2)_l-\text{R}^{22}$,

Attorney Docket No. 5573.210-US
 Pcschke et al.
 Serial No. 09/356,313 Filed July 16, 1999



wherein R^{22} , R^{23} , R^{24} , R^{25} and R^{26} independently from each other are hydrogen, halogen, aryl, hetaryl, C_{1-6} -alkyl or C_{1-6} -alkoxy;

l is 0, 1 or 2;

a is 0, 1, or 2;

b is 0, 1, or 2;

c is 0, 1, or 2;

d is 0 or 1;

e is 0, 1, 2, or 3;

f is 0 or 1;

R^5 is hydrogen or C_{1-6} -alkyl optionally substituted with one or more hydroxyl, aryl or hetaryl;

R^6 and R^7 are independently from each other hydrogen or C_{1-6} -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;

R^8 is hydrogen or C_{1-6} -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;

R^6 and R^7 or R^6 and R^8 or R^7 and R^8 may optionally form $-(CH_2)_i-U-(CH_2)_j-$, wherein i and j independently from each other are 1, 2 or 3 and U is -O-, -S-, or a valence bond;

Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

M is arylene, hetarylene, -O-, -S- or $-CR^{27}=CR^{28}-$;


R^{27} and R^{28} are independently from each other hydrogen or C_{1-6} -alkyl, optionally substituted with one or more aryl or hetaryl;

or a pharmaceutically acceptable salt thereof.

2. (Original) The compound of claim 1 wherein R^1 is C_{1-6} -alkyl.

3. (Original) The compound of claim 1 wherein R^2 is C_{1-6} -alkyl.

4. (Currently amended) The compound of claim 1 wherein L is



wherein R^4 is hydrogen or C_{1-6} alkyl;

p is 0 or 1;

q, s, t, u are independently from each other 0, 1, 2, 3 or 4;


r is 1;

the sum $q + r + s + t + u$ is 0, 1, 2, 3, or 4;

R^9 , R^{10} , R^{11} , and R^{12} are independently from each other hydrogen or C_{1-6} alkyl;

Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

Q is $>\text{N-R}^{13}$ or




wherein o is 0, 1 or 2;

T is $-\text{N}(\text{R}^{15})(\text{R}^{16})$ or hydroxyl;

R^{13} , R^{15} , and R^{16} are independently from each other hydrogen or C_{1-6} alkyl; and

R^{14} is hydrogen, aryl or hetaryl.

5. (Original) The compound of claim 1 wherein I. is



wherein q, s, t, u are independently from each other 0, 1, 2, 3 or 4;


r is 0 or 1;

the sum $q + r + s + t + u$ is 0, 1, 2, 3, or 4;

R^9 , R^{10} , R^{11} , and R^{12} are independently from each other hydrogen or C_{1-6} alkyl;

Q is $>\text{N-R}^{13}$ or

Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999




wherein o is 0, 1 or 2;

T is $-N(R^{15})(R^{16})$ or hydroxyl;

R^{13} , R^{15} , and R^{16} are independently from each other hydrogen or C_{1-6} alkyl; and


R^{14} is hydrogen, aryl or hetaryl.

6. (Original) The compound of claim 1 wherein G is



wherein R^{17} , R^{18} , R^{19} , R^{20} and R^{21} independently from each other are hydrogen, halogen, aryl, hetaryl, C_{1-6} -alkyl or C_{1-6} -alkoxy.

7. (Original) The compound of claim 1 wherein J is



wherein R^{22} , R^{23} , R^{24} , R^{25} and R^{26} independently are hydrogen, halogen, aryl, hetaryl, C_{1-6} -alkyl or C_{1-6} -alkoxy.

Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

8. (Original) The compound of claim 1 wherein M is arylene or $-\text{CR}^{27}=\text{CR}^{28}-$, wherein R^{27} and R^{28} independently are hydrogen or C_{1-6} -alkyl, optionally substituted with aryl or hetaryl.


9. (Original) The compound of claim 1 wherein R^6 and R^7 independently from each other are hydrogen or C_{1-6} -alkyl.

10. (Original) The compound of claim 1 wherein R^6 and R^7 form $-(\text{CH}_2)_i-\text{U}-(\text{CH}_2)_j-$, wherein i and j independently from each other are 1, 2 or 3 and U is $-\text{O}-$, $-\text{S}-$, or a valence bond.

11. (Original) The compound of claim 1 wherein R^8 is hydrogen or C_{1-6} -alkyl.


12. (Previously presented) The compound of claim 1 selected from

(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-((dimethylamino)methyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-((3S)-3-(dimethylaminomethyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide


Attorney Docket No. 5573.210-US
Peschke et al.
Serial No. 09/356,313 Filed July 16, 1999



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-((3S)-3-(dimethylaminomethyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-((2S)-2-((dimethylamino)methyl)pyrrolidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

N-((1R)-1-{N-[(1R)-1-Benzyl-2-((2S)-2-((dimethylamino)methyl)pyrrolidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methyl-3-((methylamino)methyl)benzamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-(dimethylamino)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-[(1R)-1-(N-methyl-N-((1R)-1-[N-methyl-N-(1-methylpiperidin-4-yl)carbamoyl]-2-phenylethyl)carbamoyl)-2-(2-naphthyl)ethyl]amide


Attorney Docket No. 5573.210-US
 Pcschke et al.
 Serial No. 09/356,313 Filed July 16, 1999



3-Aminomethyl-N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylbenzamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 3573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

(2E)-5-Amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1-{N-methyl-N-[(1R)-2-phenyl-1-((2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)amide




3-Aminomethyl-N-methyl-N-((1R)-1-{N-methyl-N-[(1R)-2-phenyl-1-((2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)benzamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-methyl-N-((1R)-1-{N-methyl-N-[(1R)-2-phenyl-1-((2,2,6,6-tetramethylpiperidin-4-yl)carbamoyl)ethyl]carbamoyl}-2-(2-naphthyl)ethyl)amide


Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-methylpiperazin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide

Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-(N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-(N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl)-2-(2-naphthyl)ethyl)-N-methylamide

Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999




(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide

Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999



(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-(4-fluorobenzyl)-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxy-4-(2-thienyl)piperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide


Attorney Docket No. 5573.210-US

Peschke et al.


Serial No. 09/356,313 Filed July 16, 1999



(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(1R)-1-(3-hydroxycyclohexylcarbonyl)-2-phenylethyl]-N-methylcarbonyl}-2-(2-naphthyl)ethyl)-N-methylamide



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-(dimethylamino)piperidin-1-yl)-2-oxoethyl]-N-methylcarbonyl}-2-(2-naphthyl)ethyl)-N-methylamide




Attorney Docket No. 5573.210-US


Peschke et al.

Serial No. 09/356,313 Filed July 16, 1999


(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1-{N-[(2R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-((2-thienyl)methyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide



(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-1-{N-[(2R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-((2-thienyl)methyl)ethyl]-N-methylcarbamoyl}-2-(2-naphthyl)ethyl)-N-methylamide




(2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-2-(biphenyl-4-yl)-1-{N-[(2R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-((2-thienyl)methyl)ethyl]-N-methylcarbamoyl}ethyl)-N-methylamide




Attorney Docket No. 5573.210-US
 Peschke et al.
 Serial No. 09/356,313 Filed July 16, 1999

(2E)-5-Amino-3,5-dimethylhex-2-enoic acid N-((1R)-2-(biphenyl-4-yl)-1-{N-[(1R)-2-(4-hydroxypiperidin-1-yl)-2-oxo-1-[(2-thienyl)methyl]ethyl]-N-methylcarbamoyl}ethyl)-N-methylamide




(2E)-5-Methyl-5-(methylamino)hex-2-enoic acid N-((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)-N-methylamide



(2E)-4-(1-Aminocyclobutyl)but-2-enoic acid ((1R)-1-{N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl}-2-(biphenyl-4-yl)ethyl)amide, or

Attorney Docket No. 5573.210-US
Peschke et al.
Serial No. 09/356,313 Filed July 16, 1999



and pharmaceutically acceptable salts thereof.

13. (Original) A method of treating growth retardation in connection with asthma, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
14. (Original) The method of claim 13, wherein the compound is a growth hormone secretagogue.
15. (Previously presented) A composition comprising, as an active ingredient, a compound of claim 1 together with a pharmaceutically acceptable carrier or diluent.
16. (Original) A method of stimulating the release of growth hormone from the pituitary of a mammal, the method comprising administering to the mammal an effective amount of a compound of claim 1 or a composition of claim 15.
17. (Original) A method of treating growth retardation in connection with juvenile rheumatic arthritis or cystic fibrosis, the method comprising administering to a subject in need thereof an effective amount of a compound of claim 1.
18. (Cancelled)